cnnm3 cbs domain (Addgene inc)
Addgene inc is a verified supplier 
91
Structured Review
Addgene inc
cnnm3 cbs domain
Cnnm3 Cbs Domain, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cnnm3+cbs+domain/CNNM3-CBS-YPet+(Plasmid+%23149686)/pmc07393355-167-6-16
Average 91 stars, based on 1 article reviews
Cnnm3 Cbs Domain, supplied by Addgene inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cnnm3+cbs+domain/CNNM3-CBS-YPet+(Plasmid+%23149686)/pmc07393355-167-6-16
Average 91 stars, based on 1 article reviews
cnnm3 cbs domain - by Bioz Stars,
2026-09
91/100 stars
Images
1) Product Images from "A FRET-based screening method to detect potential inhibitors of the binding of CNNM3 to PRL2"
Article Title: A FRET-based screening method to detect potential inhibitors of the binding of CNNM3 to PRL2
Journal: Scientific Reports
doi: 10.1038/s41598-020-69818-x
Figure Legend Snippet: CNNM3-YPet binding to CyPet-PRL2 detected by FRET. FRET data regarding the binding of CNNM3-YPet to CyPet-PRL2. R 2 = 0.9588, n = 6.
Techniques Used: Binding Assay
Figure Legend Snippet: Inhibition of the binding of CNNM3-YPet and CyPet-PRL2 using non-YPet-tagged wild-type CNNM3 CBS and mutated CNNM3 CBS. ( A ) Close-up view of the CNNM3-PRL binding site (PDB: 5K22). ( B ) Non-YPet-tagged CNNM3 CBS-based inhibition test of the binding of CNNM3-YPet (200 nM) and CyPet-PRL2 (200 nM) using FRET. All data are expressed as the mean ± SE. * p < 0.05, **** p < 0.0001, by Tukey’s multiple comparison test, n = 6.
Techniques Used: Inhibition, Binding Assay
Figure Legend Snippet: Inhibition of the binding of CNNM3-YPet and CyPet-PRL2 using non-CyPet-tagged PRL1 and PRL2. ( A ) Amino acid sequence alignment of human PRL1 (BAG70128.1) and human PRL2 (NP_001356788.1). Red boxes, identical residues; red letters, similar residues. ( B ) Structural comparison of PRL1 (blue, PDB: 1XM2) and PRL2 (orange, PDB: 5K22). ( C ) Non-CyPet PRL-based inhibition test of the binding of CNNM3-YPet (200 nM) and CyPet-PRL2 (200 nM) using FRET. All data are expressed as the mean ± SE. *** p < 0.001; **** p < 0.0001, by Tukey’s multiple comparison test, n = 6.
Techniques Used: Inhibition, Binding Assay, Sequencing
Figure Legend Snippet: Effect of divalent cations and nucleotides on the FRET intensities. ( A ) Effect of divalent cations on the binding of CNNM3-YPet (200 nM) and CyPet-PRL2 (200 nM) using FRET. Control: No additional divalent cations; Mg 2+ : 10 mM Mg 2+ was added; Zn 2+ : 10 mM Zn 2+ was added. All data are expressed as the mean ± SE. **** p < 0.0001, by Dunnett’s multiple comparison test. n = 6. ( B ) Effect of nucleotides on the binding of CNNM3-YPet (200 nM) and CyPet-PRL2 (200 nM) using FRET. Control: No additional peptide. ATP: 3 mM ATP was added; ADP: 3 mM ADP was added; AMP: 3 mM AMP was added. All data are expressed as the mean ± SE. * p < 0.05, by t -test, n = 6.
Techniques Used: Binding Assay
Figure Legend Snippet: Inhibition of the binding of CNNM3-YPet and CyPet-PRL2 by CNNM peptides. ( A ) Amino acid sequences of synthesized peptides derived from the CNNM CBS loop. Black dots show the residues replaced by cysteine in peptide 2. Red boxes, identical residues; red letters, similar residues. ( B ) Location of CNNM peptides (red) in the CNNM3 structure (PDB: 5K22). V416 and L431 are replaced by cysteine residues in peptide 2. ( C ) CNNM peptide-based inhibition test of the binding of CNNM3-YPet (200 nM) and CyPet-PRL2 (200 nM) using FRET. Control: no additional peptide; peptide 1: 100 μM peptide 1 was added; peptide 2: 100 μM peptide 2 was added. All data are expressed as the mean ± SE. * p < 0.05, by Dunnett’s multiple comparison test. n = 6. ( D ) CNNM peptide 2-based inhibition test of the binding of CNNM3-YPet (200 nM) and CyPet-PRL2 (200 nM) using FRET. Control: no additional peptide. Peptide 2: 500 μM peptide 2 was added. All data are expressed as the mean ± SE. **** p < 0.0001, by t -test, n = 6.
Techniques Used: Inhibition, Binding Assay, Synthesized, Derivative Assay
Figure Legend Snippet: Evaluation of the JMS-053 effect on the interaction between CNNM3 and PRL2. ( A ) Effect of JMS-053 on the binding of CNNM3-YPet (200 nM) and CyPet-PRL2 (200 nM) using FRET. All data are expressed as the mean ± SE. n = 6. ( B , C ) ITC data on the PRL2 with JMS-053 ( B ) and CNNM3 CBS protein ( C ). Measurements were repeated twice, and similar results were obtained.
Techniques Used: Binding Assay
Figure Legend Snippet: FRET binding model of the CNNM3 CBS domain and PRL2. ( A ) Cartoon depiction of construct design. ( B ) FRET model of the binding of CNNM3-YPet and CyPet-PRL2.
Techniques Used: Binding Assay, Construct
Related Articles
Plasmid Preparation:Article Title: A FRET-based screening method to detect potential inhibitors of the binding of CNNM3 to PRL2 Article Snippet: .. The plasmid constructs for the Construct:Article Title: A FRET-based screening method to detect potential inhibitors of the binding of CNNM3 to PRL2 Article Snippet: .. The plasmid constructs for the |